Company News

On November 14th, 2024, bioMérieux officially launched its first Data & IT Centre of Reference partnership with St James's Hospital in Dublin, Ireland. This landmark collaboration has been celebrated with an event held at the Davis Coakley Lecture Theatre, St James's Hospital.

Globally, it was estimated that approximately 4.95 million people died from Antimicrobial Resistance-related causes in 2019. And yet, one in three adults doesn’t understand what this term means. Faced with this alarming situation, an awareness-raising campaign encourages the general public to change their behaviour with regard to the use of antibiotics. Indeed, each person, at their own level, has a role to play to preserve their effectiveness.

On November 11, 2024, the Université de Sherbrooke (UdeS), the Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS) and bioMérieux, a world leader in the field of in vitro diagnostics, announce a three-year agreement to create a Canadian center of excellence dedicated to the fight against antimicrobial resistance and antibiotic stewardship.

bioMérieux, a world leader in the field of in vitro diagnostics, signed in November 2024 a Sale and Purchase Agreement (SPA) to acquire Neoprospecta. This company, based in Florianopolis, Brazil, develops and markets innovative user-friendly data and genomics solutions for augmenting quality assurance programs and improve microbiological risk prevention in food and pharma industries.

On the sidelines of the 2024 United Nations High-Level Meeting on Antimicrobial Resistance (AMR), a multisectoral event titled “Advancing Together: Securing the Global AMR Agenda by Harnessing the Collective Strength of Multi-Sector Partnerships” took place on September 24 in New York. bioMérieux, in partnership with The Wellcome Trust, The American Society of Microbiology, Malawi, and the French Republic, organized the event to focus on fostering a collaborative ecosystem that establishes sustainable solutions across the entire AMR landscape. From diagnosis and treatment to surveillance and action plans, this initiative spanned human health, animals, and the environment.